Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Poisoning
About this trial
This is an interventional prevention trial for Poisoning focused on measuring Acetylcysteine, Adverse effects, Acetaminophen, Anaphylactoid reactions
Eligibility Criteria
Inclusion Criteria:
- Healthy male, non-smoking, volunteers aged between 18-64 years
Exclusion Criteria:
- Lack of informed consent Age <18 or >64 years Current smoker Current involvement in a clinical trial Clinically significant comorbidity: heart failure, hypertension, known hyper-lipidaemia, diabetes mellitus, asthma, coagulopathy or bleeding disorders Current intake of aspirin, other non-steroid anti-inflammatory medications, or vasodilators Recent infective/inflammatory condition Recent blood donation (during the preceding three months)
Sites / Locations
- Clinical Research Facility, Royal Infirmary of EdinburghRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
Active Comparator
Active Comparator
Active Comparator
Saline
Histamine antagonists
Low dose paracetamol
High dose paracetamol
Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.